Market Research Logo

Global Overactive Bladder Therapeutics Market 2017-2021

Global Overactive Bladder Therapeutics Market 2017-2021

About Overactive Bladder (OAB) Therapeutics

Overactive bladder (OAB) is a syndrome that manifests complex symptoms such as urinary urgency with or without urinary incontinence accompanied by increased frequency and nocturia. The disease is more prevalent in women than in men, and the prevalence rate is directly proportional to age, i.e., the prevalence rate of OAB increases with the increase in age. Global OAB therapeutics market is currently dominated by anticholinergic agents, which exert its pharmacologic effect by inhibiting the neurotransmitter acetylcholine in the central and peripheral nervous system. However, the on-going research in new areas such as gene therapy can lead to change in the treatment landscape, going forward.

Technavio’s analysts forecast the global Overactive Bladder (OAB) Therapeutics market to grow at a CAGR of 1.56% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global Overactive Bladder (OAB) Therapeutics market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Overactive Bladder (OAB) Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Allergan
  • Astellas Pharma
  • Hisamitsu Pharmaceutical
  • Pfizer
Other prominent vendors
  • Ferring
  • GlaxoSmithKline
  • Ion Channel Innovations
  • Kwang Dong Pharmaceutical
  • Lanzhou Institute of Biological Products
  • Merck
  • ONO Pharmaceutical
  • Sanofi
  • Tengion
  • Teva Pharmaceutical Industries
Market driver
  • Growing geriatric population
  • For a full, detailed list, view our report
Market challenge
  • Rise in economic burden of OAB
  • For a full, detailed list, view our report
Market trend
  • Advancing biomedical science
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Table Prevalence rate of OAB in women aged under 25 years versus women aged over 65 years
    • Table OAB pathophysiology
  • Market landscape
    • Market outline
      • Table Global OAB therapeutics market snapshot
    • Market overview
    • Market size and forecast
      • Table Global OAB therapeutics market 2016-2021 ($ millions)
      • Table Opportunity analysis of global OAB therapeutics market
    • Five forces analysis
      • Table Five forces analysis
  • Pipeline analysis
    • Table Pipeline molecules at various developmental stage
    • Table Pipeline molecules arranged as per drug class
    • Table Key clinical trials
    • Table Purpose of key clinical trials
    • Management of OAB
  • Market segmentation based on drug class
    • Table Segmentation of global OAB therapeutics market by drug class 2016
    • Table Global OAB therapeutics market share by drug class, 2016
    • Table Global OAB therapeutics market segmentation by drug class 2016
    • Anticholinergic agents
      • Table Global OAB anticholinergic therapeutics market 2016-2021 ($ millions)
      • Table Types of ACh receptors
      • Table Mechanism of action of MRA
    • Beta-3-adrenoreceptor agonists
      • Table Global OAB beta-3 adrenoreceptor agonists market 2016-2021 ($ millions)
      • Table Mechanism of action of mirabegron
    • Others
  • Drug profile of key OAB therapeutics
    • Table Global OAB therapeutics market for others 2016-2021 ($ millions)
    • TOVIAZ
      • Table TOVIAZ year-over-year (YoY) revenue 2010-2016 ($ millions)
    • VESIcare
      • Table VESIcare revenue in different regions in 2015-2016 ($ millions)
    • Betanis/Myrbetriq/BETMIGA
      • Table Betanis/Myrbetriq/BETMIGA revenue in different regions 2015-2016 ($ millions)
      • Table Betanis/Myrbetriq/BETMIGA patents
      • Table History of drug approvals in OAB
  • Geographical segmentation
    • Table Segmentation of global OAB therapeutics market by geography 2016 and 2021
    • Table Global OAB therapeutics market revenue by geography 2016-2021 ($ millions)
    • Table Global OAB therapeutics market share by geography 2016-2021 (%)
    • Table Global OAB therapeutics market scenario in different regions
    • OAB therapeutics market in Americas
      • Table Market scenario in Americas
      • Table OAB therapeutics market in Americas 2016-2021 ($ millions)
      • Table Prevalence rate of OAB in US 2007
    • OAB therapeutics market in EMEA
      • Table Market scenario in EMEA
      • Table OAB therapeutics market in EMEA 2016-2021 ($ millions)
    • OAB therapeutics market in APAC
      • Table Market scenario in APAC
      • Table OAB therapeutics market in APAC 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Probability of continuing antimuscarinic treatment in patients depending on their age
      • Table Geriatric population analysis by geography 2000 and 2030 (estimated) (in millions)
      • Table Prevalence rate of OAB in different age groups in Finland 2003-2004 (%)
      • Table OAB-POLL survey in US adults 2010
    • Market challenges
      • Table Telephonic interview evaluating the treatment outcomes with antimuscarinic agents in OAB patients
  • Market trends
    • Advancing biomedical science
    • Advent of novel drug delivery systems
    • Gene therapy in OAB
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global OAB therapeutics market 2016
  • Key vendor analysis
    • Allergan
      • Table Allergan: Key highlights
      • Table Allergan: Strength assessment
      • Table Allergan: Strategy assessment
      • Table Allergan: Opportunity assessment
    • Astellas Pharma
      • Table Astellas Pharma: Key highlights
      • Table Astellas Pharma: Strength assessment
      • Table Astellas Pharma: Strategy assessment
      • Table Astellas Pharma: Opportunity assessment
    • Hisamitsu Pharmaceutical
      • Table Hisamitsu Pharmaceutical: Key highlights
      • Table Hisamitsu Pharmaceutical: Strength assessment
      • Table Hisamitsu Pharmaceutical: Strategy assessment
      • Table Hisamitsu Pharmaceutical: Opportunity assessment
    • Pfizer
      • Table Pfizer: Key highlights
      • Table Pfizer: Strength assessment
      • Table Pfizer: Strategy assessment
      • Table Pfizer: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report